Objective: to ascertain the seroprevalence of antibodies to varicella-zoster virus in the Madrid population prior to the introduction of vaccination.
INTRODUCTION
Varicella-zoster (VZV) virus belongs to the herpes virus group and causes two diseases, i.e., varicella (chickenpox) and herpes zoster. Varicella is a highly contagious, typically childhood disease having a respiratory transmission route. It develops into vesicular exanthema and fever of generally benign progression, with a low rate of complications, which tend to be more frequent among adults (1). After the primary infection, VZV remains dormant in dorsal root ganglia and can be reactivated in 15% of the population, giving rise to the clinical features of herpes zoster. Herpes zoster is more frequent in persons of advanced age, and may leave sequelae, one of the most frequent of which is postherpetic neuralgia (2-4).
The introduction of universal varicella vaccination in children has been controversial, owing to its possible effects on the disease itself and on herpes zoster (5). Initially the vaccine was exclusively used on immunodepressed patients, but subsequently its general use was authorised in a number of countries, including Japan, South Korea (6), the USA (7,8), Sweden and Germany. Since its introduction in the USA, there has been a decrease in varicella incidence and mortality (9, 10). Here in Spain, it was first introduced in 1997 for high-risk patients. In 2005 it was included in the vaccination schedule for administration to adolescents, and in 2006 the Madrid Autonomous Region (MAR) included universal varicella vaccination in its systematic vaccination schedule for children aged 15 months (11). A number of studies have targeted varicella morbidity and disease burden, as well as the cost-effectiveness and possible impact of vaccination (12) (13) (14) (15) . In addition to furnishing information on the dynamics and distribution of diseases, seroprevalence studies are a useful collaborative decision-making tool when it comes to the question of introducing vaccines (3, 16, 17) . In the case of vaccine-preventable diseases, such studies can also furnish relevant information on vaccination coverages, vaccine failures and loss of immunity.
SEROPREVALENCE OF ANTIBODIES TO VARICELLA-ZOSTER VIRUS IN MADRID (SPAIN) IN THE ABSENCE OF VACCINATION
This study sought to ascertain VZV antibody seroprevalence and its trend in the population of the Madrid Region, in the stage
